Valeant fi­nal­ly wins long-de­layed FDA OK for its glau­co­ma drug, which is more good news for Aerie

For­mer Valeant $VRX CEO Michael Pear­son (re­mem­ber him?) was will­ing to get past his gag re­flex when it came to drug R&D and cheer on the ex­per­i­men­tal la­tanoprostene bun­od oph­thalmic so­lu­tion as a block­buster in the mak­ing. Now, more than two years af­ter it was first sub­mit­ted, the FDA has sanc­tioned the drug’s mar­ket­ing af­ter Valeant was fi­nal­ly able to get past two re­jec­tions based on the agency’s prob­lems with its man­u­fac­tur­ing fa­cil­i­ty in Tam­pa.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER